Lunresertib is a small molecule commercialized by Repare Therapeutics, with a leading Phase II program in Gastroesophageal (GE) Junction Carcinomas. According to Globaldata, it is involved in 7 clinical trials, of which 5 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Lunresertib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Lunresertib is expected to reach an annual total of $60 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Lunresertib Overview

Lunresertib (RP-6306) is under development for the treatment of advanced solid tumors including metastatic colorectal cancer, ovarian, breast, hepatocellular, endometrial cancer, gastroesophageal cancer, fallopian tube cancer, peritoneal cancer, uterine cancer, triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma, non-small cell lung cancer, esophageal cancer, cholangiocarcinoma, breast cancer, head and neck cancer, soft tissue sarcoma, bladder cancer, cervical cancer, gastrointestinal stromal tumor (gist), melanoma, gallbladder cancer, vulvar cancer, sarcomas. It is administered through oral route. It acts by targeting Cyclin E 1 (CCNE1) and PKMYT1.

Repare Therapeutics Overview

Repare Therapeutics is a clinical-stage precision oncology company. Its products include lunresertib, a PKMYT1 inhibitor, camonsertib, an ATR inhibitor, RP-1664, a PLK4 inhibitor, and RP-3467, a Polo ATPase inhibitor. Repare Therapeutic utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company operates under the brand SNIPRx. It operates in the US and Canada. Repare Therapeutics is headquartered in St-Laurent, Quebec, Canada.
The company reported revenues of (US Dollars) US$51.1 million for the fiscal year ended December 2023 (FY2023), a decrease of 61.2% over FY2022. The operating loss of the company was US$116.2 million in FY2023, compared to an operating loss of US$19.8 million in FY2022. The net loss of the company was US$93.8 million in FY2023, compared to a net loss of US$29.1 million in FY2022.

For a complete picture of Lunresertib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.